Clinical relevance of CYP3A5 genotype on maraviroc exposures.

Vourvahis, Manoli; McFadyen, Lynn; Heera, Jayvant; Clark, Andrew

Vourvahis, Manoli; McFadyen, Lynn; Heera, Jayvant; Clark, Andrew.

Afiliação

Vourvahis M; Pfizer Inc., Clinical Pharmacology, New York, New York (M.V.); Pfizer Inc., Pharmacometrics, Sandwich, United Kingdom (L.M.); Pfizer Inc., Clinical Development, Groton, Connecticut (J.H.); and ViiV Healthcare, London, United Kingdom (A.C.) manoli.vourvahis@pfizer.com.
McFadyen L; Pfizer Inc., Clinical Pharmacology, New York, New York (M.V.); Pfizer Inc., Pharmacometrics, Sandwich, United Kingdom (L.M.); Pfizer Inc., Clinical Development, Groton, Connecticut (J.H.); and ViiV Healthcare, London, United Kingdom (A.C.).
Heera J; Pfizer Inc., Clinical Pharmacology, New York, New York (M.V.); Pfizer Inc., Pharmacometrics, Sandwich, United Kingdom (L.M.); Pfizer Inc., Clinical Development, Groton, Connecticut (J.H.); and ViiV Healthcare, London, United Kingdom (A.C.).
Clark A; Pfizer Inc., Clinical Pharmacology, New York, New York (M.V.); Pfizer Inc., Pharmacometrics, Sandwich, United Kingdom (L.M.); Pfizer Inc., Clinical Development, Groton, Connecticut (J.H.); and ViiV Healthcare, London, United Kingdom (A.C.).

Drug Metab Dispos ; 43(5): 771-2, 2015 May.

Article em En | MEDLINE | ID: mdl-25838402

Assuntos

Cicloexanos/farmacocinética; Citocromo P-450 CYP3A/genética; Inibidores da Fusão de HIV/farmacocinética; Voluntários Saudáveis; Triazóis/farmacocinética; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Triazóis / Cicloexanos / Inibidores da Fusão de HIV / Citocromo P-450 CYP3A / Voluntários Saudáveis Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google